{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:15:58Z","timestamp":1790403358117,"version":"4.1.0"},"reference-count":380,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Institute","doi-asserted-by":"publisher","award":["PI11\/02109"],"award-info":[{"award-number":["PI11\/02109"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Diputaci\u00f3n de Guip\u00fazcoa","award":["DFG11\/019"],"award-info":[{"award-number":["DFG11\/019"]}]},{"DOI":"10.13039\/501100003451","name":"Basque Country Government","doi-asserted-by":"publisher","award":["SAIO13-PE13BN009"],"award-info":[{"award-number":["SAIO13-PE13BN009"]}],"id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CIBERNED"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.neubiorev.2015.07.010","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T14:38:24Z","timestamp":1437921504000},"page":"294-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches"],"prefix":"10.1016","volume":"56","author":[{"given":"Haritz","family":"Jim\u00e9nez-Urbieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"de la Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Delgado-Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda C.","family":"Rodriguez-Oroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.112.196295","article-title":"Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys","volume":"343","author":"Achat-Mendes","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0010","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11060","article-title":"Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation","volume":"11","author":"Adi","year":"2007","journal-title":"Health Technol. Assess."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12031-011-9539-x","article-title":"Changes in the mRNA levels of \u03b12A and \u03b12C adrenergic receptors in rat models of Parkinson's disease and levodopa-induced dyskinesia","volume":"46","author":"Alachkar","year":"2012","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0030","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.brainres.2014.07.051","article-title":"The histone deacetylase (HDAC) inhibitor valproic acid reduces ethanol consumption and ethanol-conditioned place preference in rats","volume":"1583","author":"Al Ameri","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","article-title":"Parallel organization of functionally segregated circuits linking basal ganglia and cortex","volume":"9","author":"Alexander","year":"1986","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0040","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0045","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(08)61348-5","article-title":"Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system","volume":"99","author":"Amalric","year":"1993","journal-title":"Prog. Brain Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00213-007-0808-x","article-title":"Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats","volume":"193","author":"Amitai","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pbb.2008.08.025","article-title":"Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment","volume":"93","author":"Amitai","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tics.2013.12.003","article-title":"Inhibition and the right inferior frontal cortex","volume":"18","author":"Aron","year":"2004","journal-title":"Trends Cogn. Sci."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib0075","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.biopsych.2010.07.024","article-title":"From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses","volume":"69","author":"Aron","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib0090","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.biopsych.2006.06.038","article-title":"Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"61","author":"Aubert","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.molmed.2006.10.005","article-title":"Drug addiction: the neurobiology of disrupted self-control","volume":"12","author":"Baler","year":"2006","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0100","first-page":"515","article-title":"Aspects of hypersexuality observed in parkinsonian patients treated by Levodopa","volume":"2","author":"Ballivet","year":"1973","journal-title":"Ann. Med. Psychol. (Paris)"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A2A receptor antagonist treatment of Parkinson's disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib0115","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0120","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/mds.10551","article-title":"Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease","volume":"18","author":"Baron","year":"2003","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0125","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","article-title":"Prospective cohort study of impulse control disorders in Parkinson's disease","volume":"28","author":"Bastiaens","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0165-0173(83)90038-3","article-title":"The role of dopamine in locomotor activity and learning","volume":"287","author":"Beninger","year":"1983","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib0135","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials","volume":"26","author":"Berg","year":"2011","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib0140","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.parkreldis.2007.11.008","article-title":"Topiramate in managing impulse control disorders in Parkinson's disease","volume":"14","author":"Bermejo","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0145","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00415-010-5603-7","article-title":"Zonisamide in managing impulse control disorders in Parkinson's disease","volume":"257","author":"Bermejo","year":"2010","journal-title":"J. Neurol."},{"issue":"15","key":"10.1016\/j.neubiorev.2015.07.010_bib0150","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1523\/JNEUROSCI.5884-08.2009","article-title":"Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of levodopa-induced dyskinesia","volume":"29","author":"Berthet","year":"2009","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.alcohol.2007.11.001","article-title":"Effects of mGlu1-receptor blockade on ethanol self-administration in inbred alcohol-preferring rats","volume":"42","author":"Besheer","year":"2008","journal-title":"Alcohol"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0160","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1152\/physrev.00036.2003","article-title":"Molecular structure and physiological functions of GABA(B) receptors","volume":"84","author":"Bettler","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0165","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"Bezard","year":"2003","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.nbd.2004.10.005","article-title":"Levodopa reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain","volume":"18","author":"Bezard","year":"2005","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0175","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1017\/S0317167100010489","article-title":"Outcomes of patients with Parkinson disease and pathological gambling","volume":"37","author":"Bharmal","year":"2010","journal-title":"Can. J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease","volume":"184","author":"Bibbiani","year":"2003","journal-title":"Exp. Neurol."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0185","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/j.1460-9568.2006.04790.x","article-title":"MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation","volume":"23","author":"Bishop","year":"2006","journal-title":"Eur. J. Neurosci."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0190","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1460-9568.2012.08202.x","article-title":"Serotonin transporter inhibition attenuates levodopa-induced dyskinesia without compromising levodopa efficacy in hemi-parkinsonian rats","volume":"36","author":"Bishop","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0195","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0149-7634(96)00038-3","article-title":"Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease","volume":"21","author":"Blanchet","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0205","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1046\/j.1460-9568.2000.00089.x","article-title":"Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization in 6-hydroxidopamine-lesioned rats","volume":"12","author":"Bordet","year":"2000","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/WNF.0b013e31824d529b","article-title":"Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease","volume":"35","author":"Bosco","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0215","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0025-6196(11)60846-X","article-title":"Internet sex addiction treated with naltrexone","volume":"83","author":"Bostwick","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00002826-200401000-00008","article-title":"Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study","volume":"27","author":"Braz","year":"2004","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0225","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0896-6273(00)80374-8","article-title":"Acute effects of cocaine on human brain activity and emotion","volume":"19","author":"Breiter","year":"1997","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0230","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0896-6273(01)00303-8","article-title":"Functional imaging of neural responses to expectancy and experience of monetary gains and losses","volume":"30","author":"Breiter","year":"2001","journal-title":"Neuron"},{"issue":"4 Suppl. 1","key":"10.1016\/j.neubiorev.2015.07.010_bib0235","first-page":"S154","article-title":"Neuroimaging of dyskinesia","volume":"47","author":"Brooks","year":"2000","journal-title":"Ann. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.neubiorev.2015.07.010_bib0240","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000284626","article-title":"Buspirone in the treatment of alcoholic patients","volume":"22","author":"Bruno","year":"1989","journal-title":"Psychopathology"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0245","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/syn.20709","article-title":"The selective a1 adrenoceptor antagonist HEAT reduces levodopa-induced dyskinesia in a rat model of Parkinson's disease","volume":"64","author":"Buck","year":"2010","journal-title":"Synapse"},{"issue":"1\u20132","key":"10.1016\/j.neubiorev.2015.07.010_bib0250","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00213-002-1307-8","article-title":"Effects of fluoxetine and d-fenfluramine on cocaine-seeking behavior in rats","volume":"168","author":"Burmeister","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0255","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","article-title":"Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias","volume":"61","author":"Calon","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0260","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"issue":"Pt 5","key":"10.1016\/j.neubiorev.2015.07.010_bib0265","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awh128","article-title":"Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias","volume":"127","author":"Calon","year":"2004","journal-title":"Brain"},{"issue":"30","key":"10.1016\/j.neubiorev.2015.07.010_bib0270","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1523\/JNEUROSCI.2079-07.2007","article-title":"Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease","volume":"27","author":"Carlsson","year":"2007","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0275","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.46.6.1548","article-title":"Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease","volume":"46","author":"Carpentier","year":"1996","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib0280","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of levodopa-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib0285","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.neubiorev.2015.07.010_bib0290","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1007\/s00415-010-5715-0","article-title":"Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders","volume":"257","author":"Ceravolo","year":"2010","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0295","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/mds.24017","article-title":"Prefrontal alterations in Parkinson's disease with levodopa-induced dyskinesia during fMRI motor task","volume":"27","author":"Cerasa","year":"2012","journal-title":"Mov. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.neubiorev.2015.07.010_bib0300","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1360-0443.2006.01782.x","article-title":"Structural and metabolic brain changes in the striatum associated with methamphetamine abuse","volume":"102","author":"Chang","year":"2007","journal-title":"Addiction"},{"issue":"Suppl. 2","key":"10.1016\/j.neubiorev.2015.07.010_bib0305","first-page":"II36","article-title":"Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms","volume":"247","author":"Chase","year":"2000","journal-title":"J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.neubiorev.2015.07.010_bib0310","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0169-328X(99)00233-8","article-title":"Dopamine transporter mRNA in autopsy studies of chronic cocaine users","volume":"73","author":"Chen","year":"1999","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0315","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1371\/journal.pone.0001506","article-title":"Prelude to passion: limbic activation by \u201cunseen\u201d drug and sexual cues","volume":"3","author":"Childress","year":"2008","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib0320","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1001\/archneur.65.12.1604","article-title":"Functional abnormalities underlying pathological gambling in Parkinson disease","volume":"65","author":"Cilia","year":"2008","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0325","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.nbd.2010.03.013","article-title":"Reduced Dopamine Trasnporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling","volume":"39","author":"Cilia","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0330","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/mds.23480","article-title":"Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis","volume":"26","author":"Cilia","year":"2011","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0335","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00429-011-0314-0","article-title":"Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding","volume":"216","author":"Cilia","year":"2011","journal-title":"Brain Struct. Funct."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0340","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jnnp-2012-303988","article-title":"Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome","volume":"85","author":"Cilia","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib0345","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","article-title":"Fluoxetine and impulsive aggressive behavior in personality-disordered subjects","volume":"54","author":"Coccaro","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2015.07.010_bib0350","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.lpm.2014.02.030","article-title":"Topiramate in substance-related and addictive disorders","volume":"43","author":"Cohen","year":"2014","journal-title":"Presse Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0355","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00213-010-2154-7","article-title":"Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity","volume":"215","author":"Collins","year":"2011","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0360","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0079-6123(00)26022-6","article-title":"Reward deficiency syndrome: genetic aspects of behavioral disorders","volume":"126","author":"Comings","year":"2000","journal-title":"Prog. Brain Res."},{"issue":"16","key":"10.1016\/j.neubiorev.2015.07.010_bib0365","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0370","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuroscience.2010.04.056","article-title":"Dopamine receptor expression and distribution dynamically change in the rat nucleus accumbens after withdrawal from cocaine self-administration","volume":"169","author":"Conrad","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.017","article-title":"Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats","volume":"77","author":"Conti","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0380","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/7854_2009_24","article-title":"Imaging receptor changes in human drug abusers","volume":"3","author":"Cosgrove","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"9","key":"10.1016\/j.neubiorev.2015.07.010_bib0390","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.parkreldis.2012.05.012","article-title":"Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease","volume":"18","author":"Cunnington","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0395","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.neuron.2009.01.031","article-title":"Personality, addiction, dopamine: insights from Parkinson's disease","volume":"61","author":"Dagher","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0400","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(05)62416-6","article-title":"Zolpidem in Parkinson's disease","volume":"349","author":"Daniele","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-200301000-00001","article-title":"Topiramate for the treatment of kleptomania: a case series and review of the literature","volume":"26","author":"Dannon","year":"2003","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0410","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/01.wnf.0000152623.46474.07","article-title":"Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study","volume":"28","author":"Dannon","year":"2005","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0415","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0420","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of levodopa-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0425","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mds.23805","article-title":"Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease","volume":"27","author":"de Lau","year":"2012","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib0430","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"De la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0435","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1742-1241.2006.01167.x","article-title":"Diagnosis and treatment of obsessive-compulsive disorder and related disorders","volume":"61","author":"Dell\u2019Osso","year":"2007","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0440","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1460-9568.1996.tb01220.x","article-title":"Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum","volume":"8","author":"Doucet","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/humu.20278","article-title":"Functional polymorphisms in dopamine and serotonin pathway genes","volume":"27","author":"D'souza","year":"2006","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib0450","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-013-0066-7","article-title":"Istradefylline: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0455","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainres.2007.05.005","article-title":"The differential effects of 5-HT (1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat","volume":"1158","author":"Dupre","year":"2007","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0460","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-008-1135-6","article-title":"Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on levodopa-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat","volume":"199","author":"Dupre","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0465","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1212\/WNL.45.10.1855","article-title":"Levodopa-induced dyskinesias are improved by fluoxetine","volume":"45","author":"Durif","year":"1995","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0470","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0475","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.neuropharm.2012.06.010","article-title":"Cocaine reverses the naltrexone-induced reduction in operant ethanol self-administration: the effects on immediate-early gene expression in the rat prefrontal cortex","volume":"63","author":"Echeverry-Alzate","year":"2012","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib0480","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/mds.22974","article-title":"German competence network on Parkinson's disease. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study","volume":"25","author":"Eggert","year":"2010","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0485","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.23881","article-title":"Levodopa gains psychostimulant-like properties after nigral dopaminergic loss","volume":"74","author":"Engeln","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0490","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.nbd.2012.08.005","article-title":"Reinforcing properties of Pramipexole in normal and parkinsonian rats","volume":"49","author":"Engeln","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"18","key":"10.1016\/j.neubiorev.2015.07.010_bib0495","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1097\/00001756-200212200-00024","article-title":"Cultural objects modulate reward circuitry","volume":"13","author":"Erk","year":"2002","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0500","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib0505","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib0510","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission","volume":"59","author":"Evans","year":"2006","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0515","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/092986712803414231","article-title":"The importance of the adenosine A(2A) receptor-dopamine D(2) receptor interaction in drug addiction","volume":"19","author":"Filip","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0520","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0525","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s00415-010-5817-8","article-title":"Management of punding in Parkinson's disease: an open-label prospective study","volume":"258","author":"Fasano","year":"2011","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0530","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1124\/mol.107.043885","article-title":"Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization","volume":"74","author":"Fiorentini","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0535","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coph.2009.09.008","article-title":"Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function","volume":"10","author":"Fiorentini","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2015.07.010_bib0540","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-5793(95)00168-9","article-title":"Molecular cloning and characterisation of the gene encoding the murine D4 dopamine receptor","volume":"361","author":"Fishburn","year":"1995","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib0545","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/npp.2010.42","article-title":"Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction","volume":"35","author":"Forget","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0550","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","article-title":"Neural mechanisms underlying peakdose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan","volume":"16","author":"Fox","year":"2001","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib0555","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/mds.10693","article-title":"Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease","volume":"19","author":"Fox","year":"2004","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0560","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure","volume":"21","author":"Fox","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0565","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp.2008.154294","article-title":"BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease","volume":"80","author":"Foltynie","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"14","key":"10.1016\/j.neubiorev.2015.07.010_bib0570","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/mds.23369","article-title":"Parkinson's disease and pathological gambling: results from a functional MRI study","volume":"25","author":"Frosini","year":"2010","journal-title":"Mov. Disord."},{"issue":"11 Suppl. 6","key":"10.1016\/j.neubiorev.2015.07.010_bib0575","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1212\/01.WNL.0000095206.44418.5C","article-title":"Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease","volume":"61","author":"Fuxe","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib0580","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study","volume":"85","author":"Garcia-Ruiz","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"13","key":"10.1016\/j.neubiorev.2015.07.010_bib0585","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.neubiorev.2015.07.010_bib0590","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","article-title":"A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia","volume":"26","author":"Gardoni","year":"2006","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.neubiorev.2015.07.010_bib0595","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.neurobiolaging.2011.06.019","article-title":"Targeting NR2A-containing NMDA receptors reduces Levodopa-induced dyskinesias","volume":"33","author":"Gardoni","year":"2012","journal-title":"Neurobiol. Aging"},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0600","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0028-3908(99)00082-9","article-title":"2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist","volume":"38","author":"Gasparini","year":"1999","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib0605","first-page":"655","article-title":"mGluR5 antagonists: discovery, characterization and drug development","volume":"11","author":"Gasparini","year":"2008","journal-title":"Curr. Opin. Drug Discov. Dev."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0610","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00702-012-0818-7","article-title":"The effect of piribedil on levodopa-induced dyskinesias in a rat model of Parkinson's disease: differential role of a2 adrenergic mechanisms","volume":"120","author":"Gerlach","year":"2013","journal-title":"J. Neural Transm."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0615","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-010-1967-8","article-title":"Effects of \u03b2-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats","volume":"212","author":"Gilpin","year":"2010","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0620","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/FBP.0b013e32834f9f9d","article-title":"The potency of fluvoxamine to reduce ethanol self-administration decreases with concurrent availability of food","volume":"23","author":"Ginsburg","year":"2012","journal-title":"Behav. Pharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0625","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.biopsych.2010.08.021","article-title":"Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine","volume":"69","author":"Goeldner","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0630","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0635","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in Parkinson's disease","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"issue":"52","key":"10.1016\/j.neubiorev.2015.07.010_bib0640","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1523\/JNEUROSCI.4223-07.2007","article-title":"RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease","volume":"27","author":"Gold","year":"2007","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0645","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0022-3565(25)20396-2","article-title":"Effect of D1 and D2 agonists and antagonists on dyskinesia produced by l-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys","volume":"259","author":"Gomez-Mancilla","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0650","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","article-title":"Effect of nondopaminergic drugs on levodopa induced dyskinesias in MPTP-treated monkeys","volume":"16","author":"Gomez-Mancilla","year":"1993","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0655","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0006-8993(93)90694-I","article-title":"Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism","volume":"602","author":"Graham","year":"1993","journal-title":"Brain Res."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib0660","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s004150050530","article-title":"Risk factors for levodopa-induced dyskinesias in Parkinson's disease","volume":"246","author":"Grandas","year":"1999","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0670","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"Grant","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib0675","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v69n0511","article-title":"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges","volume":"69","author":"Grant","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0680","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of Levodopa in parkinsonian monkeys","volume":"15","author":"Gr\u00e9goire","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0685","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002109900167","article-title":"Noradrenoceptor antagonism with idazoxan improves Levodopa-induced dyskinesias in MPTP monkeys","volume":"361","author":"Grondin","year":"2000","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib0695","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1523\/JNEUROSCI.5059-04.2005","article-title":"Involvement of sensorimotor, limbic, and associative basal ganglia domains in l-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"25","author":"Guigoni","year":"2005","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0700","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.nbd.2007.02.001","article-title":"Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates","volume":"26","author":"Guigoni","year":"2007","journal-title":"Neurobiol. Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.neubiorev.2015.07.010_bib0705","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1353-8020(09)70783-7","article-title":"Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia","volume":"15","author":"Guigoni","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0710","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.neuroscience.2014.10.008","article-title":"The place of dopamine in the cortico-basal ganglia circuit","volume":"282C","author":"Haber","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0715","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson's disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0720","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"48","author":"Hallett","year":"2005","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0725","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchemneu.2003.10.003","article-title":"The primate basal ganglia: parallel and integrative networks","volume":"26","author":"Haber","year":"2003","journal-title":"J. Chem. Neuroanat."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0730","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00002512-200522060-00002","article-title":"Adenosine A2A receptor antagonists for Parkinson's disease rationale, therapeutic potential and clinical experience","volume":"22","author":"Hauser","year":"2005","journal-title":"Drugs Aging"},{"issue":"15","key":"10.1016\/j.neubiorev.2015.07.010_bib0735","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/mds.22095","article-title":"Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations","volume":"23","author":"Hauser","year":"2008","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0740","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","article-title":"Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial","volume":"10","author":"Hauser","year":"2011","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0745","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.neubiorev.2011.03.005","article-title":"5-HT receptors and reward-related behaviour: a review","volume":"35","author":"Hayes","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0750","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbr.2008.08.021","article-title":"The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat","volume":"197","author":"H\u00e4ggkvist","year":"2009","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0755","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","article-title":"Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"171","author":"Henry","year":"2001","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0760","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0014-4886(03)00064-5","article-title":"Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease","volume":"183","author":"Henry","year":"2003","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0765","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.47.1.219","article-title":"Consequence of nigrostriatal denervation and Levodopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum","volume":"47","author":"Herrero","year":"1996","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.neubiorev.2015.07.010_bib0770","doi-asserted-by":"crossref","first-page":"12016","DOI":"10.1073\/pnas.95.20.12016","article-title":"Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias","volume":"95","author":"Hershey","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0775","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.parkreldis.2011.03.003","article-title":"Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease","volume":"17","author":"Hicks","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Suppl. 2","key":"10.1016\/j.neubiorev.2015.07.010_bib0780","first-page":"S281","article-title":"ADX48621, a novel mGlu5 negative allosteric modulator alleviates levodopa-induced chorea and dystonia in the MPTP lesioned macaque model of Parkinson's disease","volume":"25","author":"Hill","year":"2010","journal-title":"Mov. Disord."},{"issue":"20","key":"10.1016\/j.neubiorev.2015.07.010_bib0785","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1074\/jbc.M107731200","article-title":"Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors","volume":"277","author":"Hillion","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.neubiorev.2015.07.010_bib0790","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1523\/JNEUROSCI.0582-08.2008","article-title":"Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease","volume":"28","author":"Hirano","year":"2008","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib0795","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00213-005-0217-y","article-title":"The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL\/6J mice","volume":"183","author":"Hodge","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"issue":"5544","key":"10.1016\/j.neubiorev.2015.07.010_bib0800","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1126\/science.294.5544.980","article-title":"\u2018Behavioral\u2019 addictions: do they exist?","volume":"294","author":"Holden","year":"2001","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0805","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neubiorev.2011.06.001","article-title":"Serotonin and decision making processes","volume":"36","author":"Homberg","year":"2012","journal-title":"Neurosci Biobehav Rev."},{"issue":"5943","key":"10.1016\/j.neubiorev.2015.07.010_bib0810","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/306611a0","article-title":"Isolation and structural organization of the human preproenkephalin B gene","volume":"306","author":"Horikawa","year":"1983","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib0815","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12264-014-1469-5","article-title":"Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings","volume":"30","author":"Hou","year":"2014","journal-title":"Neurosci. Bull."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0820","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/jpet.112.195693","article-title":"L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"342","author":"Huot","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0825","doi-asserted-by":"crossref","first-page":"207.e9","DOI":"10.1016\/j.neurobiolaging.2010.09.011","article-title":"Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque","volume":"33","author":"Huot","year":"2012","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0835","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of levodopa-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib0840","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1021271029163","article-title":"Genetics of pathological gambling","volume":"19","author":"Ib\u00e1\u00f1ez","year":"2003","journal-title":"J. Gambl. Stud."},{"issue":"27","key":"10.1016\/j.neubiorev.2015.07.010_bib0845","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1523\/JNEUROSCI.23-27-09107.2003","article-title":"3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates","volume":"23","author":"Iravani","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0855","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2047-9158-4-3","article-title":"Treatment of the later stages of Parkinson's disease \u2013 pharmacological approaches now and in the future","volume":"4","author":"Jenner","year":"2015","journal-title":"Transl. Neurodegener."},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib0860","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/FPC.0000000000000056","article-title":"COMT gene and risk for Parkinson's disease: a systematic review and meta-analysis","volume":"24","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"issue":"36","key":"10.1016\/j.neubiorev.2015.07.010_bib0865","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1073\/pnas.0403743101","article-title":"Changes in connectivity profiles define functionally distinct regions in human medial frontal cortex","volume":"101","author":"Johansen-Berg","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0870","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/nbdi.2000.0372","article-title":"Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia","volume":"8","author":"Johansson","year":"2001","journal-title":"Neurobiol. Dis."},{"issue":"13","key":"10.1016\/j.neubiorev.2015.07.010_bib0875","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/mds.23172","article-title":"The a2 adrenergic antagonist fipamezole improves quality of levodopa action in parkinsonian primates","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0880","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.parkreldis.2012.06.005","article-title":"Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease","volume":"18","author":"Joutsa","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib0885","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/mds.24941","article-title":"Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders","volume":"27","author":"Joutsa","year":"2012","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0895","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.npp.1300338","article-title":"Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats","volume":"29","author":"June","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0900","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1006\/exnr.2000.7350","article-title":"Combined use of the adenosine A2A antagonist KW-6002 with or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys","volume":"162","author":"Kanda","year":"2000","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0905","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0304-3940(94)11192-L","article-title":"Immunocytochemical localization of mu-opioid receptor in the rat caudate-putamen","volume":"184","author":"Kaneko","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0910","first-page":"1346","article-title":"Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered levodopa in the striatum with nigrostriatal denervation","volume":"76","author":"Kannari","year":"2001","journal-title":"J. Neuro-chem."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0915","first-page":"133","article-title":"Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease","volume":"54","author":"Kannari","year":"2002","journal-title":"No To Shinkei"},{"issue":"11","key":"10.1016\/j.neubiorev.2015.07.010_bib0920","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.WNL.0000068009.32067.A1","article-title":"Levodopa-induced adverse effects in PD and dopamine transporter gene polymorphism","volume":"60","author":"Kaiser","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0925","first-page":"295","article-title":"Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study","volume":"75","author":"Katzenschlager","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"Pt 7","key":"10.1016\/j.neubiorev.2015.07.010_bib0930","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/brain\/awu117","article-title":"Targeting impulsivity in Parkinson's disease using atomoxetine","volume":"137","author":"Kehagia","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0935","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1196\/annals.1300.040","article-title":"Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats","volume":"1003","author":"Kenny","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0940","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/add.12261","article-title":"Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial","volume":"108","author":"King","year":"2013","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib0945","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.neuropharm.2011.03.022","article-title":"Contributions of serotonin in addiction vulnerability","volume":"61","author":"Kirby","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0950","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nn1699","article-title":"BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex","volume":"9","author":"Kleim","year":"2006","journal-title":"Nat. Neurosci."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib0955","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00702-002-0715-6","article-title":"Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism","volume":"109","author":"Klintenberg","year":"2002","journal-title":"J. Neural Transm."},{"issue":"16","key":"10.1016\/j.neubiorev.2015.07.010_bib0960","doi-asserted-by":"crossref","first-page":"RC159","DOI":"10.1523\/JNEUROSCI.21-16-j0002.2001","article-title":"Anticipation of increasing monetary reward selectively recruits nucleus accumbens","volume":"21","author":"Knutson","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0965","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.tips.2011.02.005","article-title":"Structural insights into adrenergic receptor function and pharmacology","volume":"32","author":"Kobilka","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0970","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1471-4159.2010.06776.x","article-title":"Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"114","author":"Kobylecki","year":"2010","journal-title":"J. Neurochem."},{"issue":"13","key":"10.1016\/j.neubiorev.2015.07.010_bib0975","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/mds.23867","article-title":"Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease","volume":"26","author":"Kobylecki","year":"2011","journal-title":"Mov. Disord."},{"issue":"6682","key":"10.1016\/j.neubiorev.2015.07.010_bib0980","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/30498","article-title":"Evidence for striatal dopamine release during a video game","volume":"393","author":"Koepp","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib0985","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.54.8.1589","article-title":"AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys","volume":"54","author":"Konitsiotis","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib0990","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4088\/JCP.v64n0709","article-title":"Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation","volume":"64","author":"Koran","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib0995","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00213-007-1030-6","article-title":"The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram","volume":"197","author":"Kuan","year":"2008","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1000","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.10625","article-title":"Disabling repetitive behaviors in Parkinson's disease","volume":"19","author":"Kurlan","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1010","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1586\/14737175.8.8.1189","article-title":"Effectiveness of benzodiazepines: do they work or not?","volume":"8","author":"Lader","year":"2006","journal-title":"Expert Rev. Neurother."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/syn.890200406","article-title":"D3 and D2 dopamine receptors: visualization of cellular expression patterns in motor and limbic structures","volume":"20","author":"Larson","year":"1995","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FBP.0b013e3283242f05","article-title":"Genetics of dopamine receptors and drug addiction: a comprehensive review","volume":"20","author":"Le Foll","year":"2009","journal-title":"Behav. Pharmacol."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib1030","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/mds.22678","article-title":"Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease","volume":"24","author":"Lee","year":"2009","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mds.23400","article-title":"Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease","volume":"26","author":"Lee","year":"2011","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.parkreldis.2011.08.009","article-title":"Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease","volume":"18","author":"Lee","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1045","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00213-011-2550-7","article-title":"Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity","volume":"219","author":"Leeman","year":"2012","journal-title":"Psychopharmacology (Berl.)"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1050","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mds.23983","article-title":"Perampanel, an AMPA antagonist, found to have no benefit in reducing \u201coff\u201d time in Parkinson's disease","volume":"27","author":"Lees","year":"2012","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1055","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1532-5415.2009.01911.x","article-title":"Quetiapine-induced dystonia and agitation in Parkinson's disease with dementia: a case report","volume":"57","author":"Leey","year":"2009","journal-title":"J. Am. Geriatr. Soc."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1060","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1046\/j.1471-4159.1999.01982.x","article-title":"Regulation of rat dopamine transporter mRNA and protein by chronic cocaine administration","volume":"73","author":"Letchworth","year":"1999","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib1065","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1523\/JNEUROSCI.21-08-02799.2001","article-title":"Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys","volume":"21","author":"Letchworth","year":"2001","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1212\/WNL.0b013e31825f0451","article-title":"Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)","volume":"79","author":"Lewitt","year":"2012","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib1075","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2006.04.003","article-title":"Behavioral and neurochemical interactions between group I mGluR antagonists and ethanol: potential insight into their anti-addictive properties","volume":"85","author":"Lominac","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1085","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neulet.2013.10.013","article-title":"Acute and subchronic effects of buspirone on attention and impulsivity in the five-choice serial reaction time task in rats","volume":"556","author":"Lu","year":"2013","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1090","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1095","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1196\/annals.1441.013","article-title":"Correlating human and animal studies of cocaine abuse and gene expression","volume":"1141","author":"Lull","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ana.410310514","article-title":"Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys","volume":"31","author":"Luquin","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1105","first-page":"118","article-title":"Gender differences in Parkinson's disease","volume":"21","author":"Lyons","year":"1998","journal-title":"Clin. Neuropharmacol."},{"issue":"15","key":"10.1016\/j.neubiorev.2015.07.010_bib1110","first-page":"2102","article-title":"Latest advancements in the pharmacological treatment of binge eating disorder","volume":"16","author":"Marazziti","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1531-8257(200003)15:2<336::AID-MDS1023>3.0.CO;2-R","article-title":"Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease","volume":"15","author":"Manson","year":"2000","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1120","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/jnnp.70.4.554","article-title":"High dose naltrexone for dyskinesias induced by levodopa","volume":"70","author":"Manson","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-008-1452-9","article-title":"Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"204","author":"Marin","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nbd.2013.12.009","article-title":"Early l-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats","volume":"64","author":"Marin","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1135","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.109.151357","article-title":"Dissociation of the effects of MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]piperidine] on conditioned reinstatement and reinforcement: comparison between cocaine and a conventional reinforcer","volume":"329","author":"Martin-Fardon","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1749-6632.1999.tb09286.x","article-title":"D3 dopamine and kappa opioid receptor alterations in human brain of cocaine-overdose victims","volume":"877","author":"Mash","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1145","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1471-4159.2002.00820.x","article-title":"Dopamine transport function is elevated in cocaine users","volume":"81","author":"Mash","year":"2002","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1150","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1046\/j.1471-4159.1996.66030915.x","article-title":"Low levels of mRNA for dopamine D4 receptor in human cerebral cortex and striatum","volume":"66","author":"Matsumoto","year":"1996","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1160","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib1165","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.4088\/JCP.v67n1209","article-title":"Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial","volume":"67","author":"McElroy","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/TCRM.S25574","article-title":"Pharmacological management of binge eating disorder: current and emerging treatment options","volume":"8","author":"McElroy","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/10550490490265325","article-title":"A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals","volume":"13","author":"McRae","year":"2004","journal-title":"Am. J. Addict."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/10550490600860635","article-title":"Buspirone for treatment of marijuana dependence: a pilot study","volume":"15","author":"McRae","year":"2006","journal-title":"Am. J. Addict."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib1185","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0006-3223(93)90178-G","article-title":"Effects of cocaine on dopamine receptor gene expression: a study in the postmortem human brain","volume":"34","author":"Meador-Woodruff","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1190","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0165-0173(98)00052-6","article-title":"An update on GABAA receptors","volume":"29","author":"Mehta","year":"1999","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"21","key":"10.1016\/j.neubiorev.2015.07.010_bib1195","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1073\/pnas.90.21.9954","article-title":"Cloning and pharmacological characterization of a rat kappa opioid receptor","volume":"90","author":"Meng","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1200","first-page":"273","article-title":"Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study","volume":"22","author":"Merello","year":"1999","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1205","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1756285613476127","article-title":"Diagnosis and treatment of impulse control disorders in patients with movement disorders","volume":"6","author":"Mestre","year":"2013","journal-title":"Ther. Adv. Neurol Disord."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1215","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0269881108098146","article-title":"Methylphenidate-induced impulsivity: pharmacological antagonism by beta-adrenoreceptor blockade","volume":"24","author":"Milstein","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0168-0102(95)00933-K","article-title":"Molecular biology of the opioid receptors: structures, functions and distributions","volume":"23","author":"Minami","year":"1995","journal-title":"Neurosci. Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0740-5472(01)00202-1","article-title":"The impact of impulsivity on cocaine use and retention in treatment","volume":"21","author":"Moeller","year":"2001","journal-title":"J. Subst. Abuse Treat."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1235","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1240","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0149-7634(96)00035-8","article-title":"Glutamate antagonists and Parkinson's disease: a review of clinical data","volume":"21","author":"Montastruc","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1250","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1037\/a0028615","article-title":"randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men","volume":"80","author":"Morgenstern","year":"2012","journal-title":"J. Consult Clin. Psychol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1255","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.neuropharm.2013.05.028","article-title":"Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in Levodopa-treated parkinsonian monkeys","volume":"73","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"Zonisamide improves motor function in Parkinson's disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1265","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mds.26068","article-title":"Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease","volume":"30","author":"Napier","year":"2015","journal-title":"Mov. Disord."},{"issue":"Suppl. 20","key":"10.1016\/j.neubiorev.2015.07.010_bib1270","first-page":"18","article-title":"The role of selective serotonin reuptake inhibitors in reducing alcohol consumption","volume":"62","author":"Naranjo","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1275","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.nbd.2010.11.007","article-title":"Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease","volume":"41","author":"Navailles","year":"2011","journal-title":"Neurobiol. Dis."},{"issue":"1507","key":"10.1016\/j.neubiorev.2015.07.010_bib1280","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1098\/rstb.2008.0067","article-title":"Review. Transcriptional mechanisms of addiction: role of DeltaFosB","volume":"363","author":"Nestler","year":"2008","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1285","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","article-title":"Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties","volume":"216","author":"Newman-Tancredi","year":"2011","journal-title":"Psychopharmacology (Berl.)"},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1290","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","article-title":"Serotonin receptors","volume":"108","author":"Nichols","year":"2008","journal-title":"Chem. Rev."},{"issue":"7\u20138","key":"10.1016\/j.neubiorev.2015.07.010_bib1295","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","article-title":"Metabotropic glutamate receptors: from the workbench to the bedside","volume":"60","author":"Nicoletti","year":"2011","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1300","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0301-0082(02)00011-4","article-title":"Dopamine and the regulation of cognition and attention","volume":"67","author":"Nieoullon","year":"2002","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1305","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0306-4522(94)00606-6","article-title":"Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease","volume":"66","author":"Nisbet","year":"1995","journal-title":"Neuroscience"},{"issue":"5846","key":"10.1016\/j.neubiorev.2015.07.010_bib1310","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/295202a0","article-title":"Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin","volume":"295","author":"Noda","year":"1982","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nrn3939","article-title":"The dopamine theory of addiction: 40 years of highs and lows","volume":"16","author":"Nutt","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1320","first-page":"S30","article-title":"The basal ganglia in Parkinson's disease: current concepts and unexplained observations","volume":"64 Suppl. 2","author":"Obeso","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1325","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1002\/mds.22062","article-title":"Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease","volume":"23 Suppl. 3","author":"Obeso","year":"2008","journal-title":"Mov. Disord."},{"issue":"9942","key":"10.1016\/j.neubiorev.2015.07.010_bib1330","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(13)62418-6","article-title":"The expanding universe of disorders of the basal ganglia","volume":"384","author":"Obeso","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1335","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","article-title":"Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models","volume":"177","author":"Oh","year":"2002","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1340","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1254\/jphs.12264FP","article-title":"Tandospirone suppresses impulsive action by possible blockade of the 5-HT1A receptor","volume":"122","author":"Ohmura","year":"2013","journal-title":"J. Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib1345","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1468-1331.2011.03432.x","article-title":"Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework","volume":"18","author":"Okai","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1350","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin. Neuropharmacol."},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib1355","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib1360","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1212\/WNL.53.7.1425","article-title":"Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD","volume":"53","author":"Oliveri","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1365","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","article-title":"Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial","volume":"82","author":"Ory-Magne","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1370","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome","volume":"23","author":"O'Sullivan","year":"2009","journal-title":"CNS Drugs"},{"issue":"Pt 4","key":"10.1016\/j.neubiorev.2015.07.010_bib1375","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/brain\/awr003","article-title":"Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours","volume":"134","author":"O'Sullivan","year":"2011","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neubiorev.2015.07.010_bib1380","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/npp.2011.77","article-title":"Inhibition of \u03b2-adrenergic receptors induces a persistent deficit in retrieval of a cocaine-associated memory providing protection against reinstatement","volume":"36","author":"Otis","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1385","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuroscience.2010.03.022","article-title":"Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias","volume":"167","author":"Ouattara B1","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/SAR.S45666","article-title":"Nalmefene: a new approach to the treatment of alcohol dependence","volume":"5","author":"Paille","year":"2014","journal-title":"Subst. Abuse Rehabil."},{"issue":"9","key":"10.1016\/j.neubiorev.2015.07.010_bib1395","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","article-title":"Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study","volume":"83","author":"Papay","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1400","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","article-title":"Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res. Rev."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib1405","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1001\/archneur.58.10.1660","article-title":"Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease","volume":"58","year":"2001","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1415","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-003-1432-z","article-title":"The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice","volume":"167","author":"Paterson","year":"2003","journal-title":"Psychopharmacology (Berl.)"},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib1420","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.neuropharm.2010.01.003","article-title":"MK-801 inhibits levodopa-induced abnormal involuntary movements only at doses that worsen parkinsonism","volume":"58","author":"Paquette","year":"2010","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.neubiorev.2015.07.010_bib1425","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1111\/j.1460-9568.2012.08243.x","article-title":"Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors","volume":"36","author":"Paquette","year":"2012","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1430","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.870130207","article-title":"De novo administration of ropinirole and bromocriptine induces less dyskinesia than Levodopa in the MPTP-treated marmoset","volume":"13","author":"Pearce","year":"1998","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib1435","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/WNF.0b013e31826e6e6d","article-title":"Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease","volume":"35","author":"Perez-Lloret","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1440","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tins.2005.03.004","article-title":"Homeostatic plasticity and NMDA receptor trafficking","volume":"28","author":"P\u00e9rez-Ota\u00f1o","year":"2005","journal-title":"Trends Neurosci."},{"issue":"42","key":"10.1016\/j.neubiorev.2015.07.010_bib1445","doi-asserted-by":"crossref","first-page":"10509","DOI":"10.1523\/JNEUROSCI.2807-08.2008","article-title":"Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses","volume":"28","author":"Petrovic","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1450","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fpsyt.2012.00102","article-title":"Amantadine in the treatment of pathological gambling: a case report","volume":"3","author":"Pettorruso","year":"2012","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1455","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.neubiorev.2015.07.010_bib1460","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/j.parkreldis.2008.04.019","article-title":"Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD","volume":"14","author":"Picconi","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Pt 2","key":"10.1016\/j.neubiorev.2015.07.010_bib1465","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/brain\/awq342","article-title":"Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia","volume":"134","author":"Picconi","year":"2011","journal-title":"Brain"},{"issue":"Pt 2","key":"10.1016\/j.neubiorev.2015.07.010_bib1475","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/brain\/aws326","article-title":"Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease","volume":"136","author":"Politis","year":"2013","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1480","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharmthera.2013.12.012","article-title":"Metabotropic glutamatergic receptors and their ligands in drug addiction","volume":"142","author":"Pomierny-Chamio\u0142o","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1485","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/jnnp-2012-302684","article-title":"Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic","volume":"84","author":"Pondal","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1495","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1098\/rstb.2008.0100","article-title":"Review: the neurobiology of pathological gambling and drug addiction: an overview and new findings","volume":"363","author":"Potenza","year":"2008","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1500","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.870040301","article-title":"Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease","volume":"4","author":"Pourcher","year":"1989","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1505","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pharep.2013.10.001","article-title":"Clinical approaches to treatment of Internet addiction","volume":"66","author":"Przepiorka","year":"2014","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1510","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1515","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/157488612800492726","article-title":"Impulsive and compulsive behaviours during dopamine replacement treatment in Parkinson's Disease and other disorders","volume":"7","author":"Raja","year":"2012","journal-title":"Curr. Drug Saf."},{"issue":"21","key":"10.1016\/j.neubiorev.2015.07.010_bib1520","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0b013e31821ccce4","article-title":"Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease","volume":"76","author":"Ramlackhansingh","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neubiorev.2015.07.010_bib1525","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/mds.23147","article-title":"Decreased ventral striatal activity with impulse control disorders in Parkinson's disease","volume":"25","author":"Rao","year":"2010","journal-title":"Mov. Disord."},{"issue":"4.","key":"10.1016\/j.neubiorev.2015.07.010_bib1530","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/mds.870090410","article-title":"Naltrexone, an opiate antagonist, fails to modify motor signs in patients with Parkinson's disease","volume":"9","author":"Rascol","year":"1994","journal-title":"Mov. Disord."},{"issue":"Pt 3","key":"10.1016\/j.neubiorev.2015.07.010_bib1535","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/brain\/121.3.527","article-title":"Cortical motor overactivation in parkinsonian patients with Levodopa-induced peak-dose dyskinesia","volume":"121","author":"Rascol","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1540","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1545","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","article-title":"Idazoxan, an alpha-2 antagonist, and Levodopa-induced dyskinesias in patients with Parkinson's disease","volume":"16","author":"Rascol","year":"2001","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1550","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/WNF.0b013e318241520b","article-title":"Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone","volume":"35","author":"Rascol","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1555","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.nbd.2012.06.021","article-title":"Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study","volume":"48","author":"Ray","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1560","first-page":"56","article-title":"Augmentation with naltrexone to treat compulsive sexual behavior: a case series","volume":"22","author":"Raymond","year":"2010","journal-title":"Ann. Clin. Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.neubiorev.2015.07.010_bib1565","article-title":"Long-term treatment with dopamine agonists in idiopathic Parkinson's disease","volume":"247","author":"Reichmann","year":"2000","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1570","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nn1378","article-title":"Pathological gambling is linked to reduced activation of the mesolimbic reward system","volume":"8","author":"Reuter","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib1575","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bcp.2013.08.005","article-title":"Basal ganglia serotonin 1B receptors in parkinsonian monkeys with l-DOPA-induced dyskinesia","volume":"86","author":"Riahi","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1580","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbr.2012.04.027","article-title":"Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls","volume":"233","author":"Riddle","year":"2012","journal-title":"Behav. Brain Res."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1585","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2217\/pgs.12.149","article-title":"DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients","volume":"13","author":"Rieck","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1590","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.870120204","article-title":"The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys","volume":"12","author":"Rioux","year":"1997","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1595","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.0022-3042.2001.00702.x","article-title":"Dopamine D4 receptors are heterogeneously distributed in the striosomes\/matrix compartments of the striatum","volume":"80","author":"Rivera","year":"2002","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1600","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1460-9568.2004.03591.x","article-title":"Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease","volume":"20","author":"Robelet","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib1605","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/sj.npp.1301636","article-title":"Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task","volume":"33","author":"Robinson","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1610","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jneumeth.2011.04.025","article-title":"Intracranial self-stimulation as a positive reinforcer to study impulsivity in a probability discounting paradigm","volume":"198","author":"Rokosik","year":"2011","journal-title":"J. Neurosci. Methods"},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib1615","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1124\/mol.110.067207","article-title":"Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity","volume":"78","author":"Rodriguez","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib1620","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1474-4422(09)70293-5","article-title":"Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms","volume":"8","author":"Rodriguez-Oroz","year":"2009","journal-title":"Lancet Neurol."},{"issue":"Pt 1","key":"10.1016\/j.neubiorev.2015.07.010_bib1625","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/brain\/awq301","article-title":"Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease","volume":"134","author":"Rodriguez-Oroz","year":"2011","journal-title":"Brain"},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2015.07.010_bib1630","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2006.07.017","article-title":"The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets","volume":"546","author":"Rose","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1635","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.brainres.2006.10.038","article-title":"The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats","volume":"1133","author":"Rose","year":"2007","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1640","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1096-9861(19981116)401:2<163::AID-CNE2>3.0.CO;2-D","article-title":"Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system","volume":"401","author":"Rosin","year":"1998","journal-title":"J. Comp. Neurol."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib1645","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/mds.23177","article-title":"Clozapine for medication-related pathological gambling in Parkinson disease","volume":"25","author":"Rotondo","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1650","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/1531-8257(200007)15:4<734::AID-MDS1022>3.0.CO;2-E","article-title":"Subhypnotic doses of Zolpidem oppose dopaminergic induced dyskinesia on Parkinson's disease","volume":"15","author":"Ruzicka","year":"2000","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1655","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of levodopa-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1660","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1665","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.neubiorev.2015.07.010_bib1670","first-page":"S277","article-title":"Pilot study of the efficacy and safety of Piclozotan in Parkinson's disease patients with Levodopa induced motor complications","volume":"24","author":"Sage","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1675","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0028-3908(03)00249-1","article-title":"Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems","volume":"45","author":"Samadi","year":"2003","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1680","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.nbd.2004.02.002","article-title":"The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys","volume":"16","author":"Samadi","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1685","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mds.26099","article-title":"Management of impulse control disorders in Parkinson's disease: controversies and future approaches","volume":"30","author":"Samuel","year":"2015","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib1695","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","article-title":"Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"18","author":"Savola","year":"2003","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1705","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1474-4422(06)70411-2","article-title":"Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism","volume":"5","author":"Schrag","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1710","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s00213-005-2175-9","article-title":"The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats","volume":"179","author":"Schroeder","year":"2005","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1715","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0169-328X(97)00025-9","article-title":"Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities","volume":"45","author":"Segal","year":"1997","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1725","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.parkreldis.2010.06.003","article-title":"Classifying risk factors for dyskinesia in Parkinson's disease","volume":"16","author":"Sharma","year":"2010","journal-title":"Park. Rel. Dis."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/0972-2327.144311","article-title":"Impulse control disorders and related behaviors (ICD-RBs) in Parkinson's disease patients: Assessment using \u201cQuestionnaire for impulsive-compulsive disorders in Parkinson's disease\u201d (QUIP)","volume":"18","author":"Sharma","year":"2015","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1735","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.drugalcdep.2013.01.003","article-title":"Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats","volume":"129","author":"Shelton","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib1740","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/mds.21118","article-title":"Punding and dyskinesias","volume":"21","author":"Silveira-Moriyama","year":"2006","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib1745","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.parkreldis.2013.03.016","article-title":"Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia","volume":"19","author":"Silver","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1750","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1006\/exnr.2001.7854","article-title":"Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia","volume":"174","author":"Silverdale","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1755","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/mds.20345","article-title":"Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"20","author":"Silverdale","year":"2005","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1760","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/syn.20739","article-title":"Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate","volume":"64","author":"Silverdale","year":"2010","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1765","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/01.WNF.0000220818.71231.DF","article-title":"Switching from levodopa to the long-acting dopamine D2\/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates","volume":"29","author":"Smith","year":"2006","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1770","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00415-012-6669-1","article-title":"Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease","volume":"260","author":"Sriram","year":"2013","journal-title":"J. Neurol."},{"issue":"Pt 5","key":"10.1016\/j.neubiorev.2015.07.010_bib1775","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/brain\/awp054","article-title":"Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C]raclopride PET study","volume":"132","author":"Steeves","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1780","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1016\/S0021-9258(19)50445-8","article-title":"Adenosine receptors","volume":"267","author":"Stiles","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.neubiorev.2015.07.010_bib1785","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi","year":"2013","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1790","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0304-3940(95)12021-U","article-title":"Genomic structure and tissue distribution of the mouse dopamine D4 receptor","volume":"199","author":"Suzuki","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1795","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E","article-title":"Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study","volume":"27","author":"Svenningsson","year":"1997","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1810","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas","year":"2010","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1815","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial","volume":"169","author":"Tiihonen","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1820","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neures.2005.03.004","article-title":"A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease","volume":"52","author":"Tomiyama","year":"2005","journal-title":"Neurosci. Res."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1825","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1830","doi-asserted-by":"crossref","DOI":"10.1002\/mds.26199","article-title":"Selective dysfunction of basal ganglia subterritories: from movement to behavioral disorders","author":"Tremblay","year":"2015","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.neubiorev.2015.07.010_bib1835","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(03)00183-9","article-title":"Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures","volume":"116","author":"Ueda","year":"2003","journal-title":"Brain. Res. Mol. Brain Res."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1840","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/(SICI)1096-8628(19970725)74:4<439::AID-AJMG16>3.0.CO;2-J","article-title":"High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers","volume":"74","author":"Vandenbergh","year":"1997","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1845","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fncel.2014.00466","article-title":"Glutamatergic synaptic plasticity in the mesocorticolimbic system in addiction","volume":"8","author":"van Huijstee","year":"2015","journal-title":"Front. Cell Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1850","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.parkreldis.2011.10.019","article-title":"Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders","volume":"18","author":"Vallelunga","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1855","first-page":"220","article-title":"Acute chorea caused by valproate in an elderly","volume":"111","author":"van de Velde","year":"2011","journal-title":"Acta Neurol Belg."},{"issue":"19","key":"10.1016\/j.neubiorev.2015.07.010_bib1860","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/WNL.0b013e3181fc27fa","article-title":"Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD","volume":"75","author":"Van Eimeren","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1865","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.63.2.205","article-title":"Levodopa associated dyskinesia risk among Parkinson disease patients in Olmstead County, Minnesota, 1976\u20131990","volume":"63","author":"Van Garpen","year":"2006","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.neubiorev.2015.07.010_bib1870","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1875","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2008.11.010","article-title":"Dopamine D3 receptor stimulation underlies the development of levodopa-induced dyskinesia in animal models of Parkinson's disease","volume":"35","author":"Visanji","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1880","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib1885","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1176\/ajp.155.10.1325","article-title":"Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate","volume":"155","author":"Volkow","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.neubiorev.2015.07.010_bib1890","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.64.8.1089","article-title":"Medication-related impulse control and repetitive behaviors in Parkinson disease","volume":"64","author":"Voon","year":"2007","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1895","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/WCO.0b013e3283489687","article-title":"Impulse control disorders in Parkinson's disease: recent advances","volume":"24","author":"Voon","year":"2011","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1900","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/jnnp-2013-305395","article-title":"Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels","volume":"85","author":"Voon","year":"2014","journal-title":"J. Neurol Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2015.07.010_bib1905","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/mds.25886","article-title":"Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease","volume":"29","author":"Vriend","year":"2014","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib1910","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.4088\/JCP.v67n1218","article-title":"A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men","volume":"67","author":"Wainberg","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2015.07.010_bib1915","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/WNL.56.12.1757","article-title":"Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD","volume":"56","author":"Wang","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neubiorev.2015.07.010_bib1920","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0304-3940(01)01971-1","article-title":"Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease","volume":"308","author":"Wang","year":"2001","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(02)13011-7","article-title":"GABA and GABA receptors in the central nervous system and other organs","volume":"213","author":"Watanabe","year":"2002","journal-title":"Int. Rev. Cytol."},{"issue":"4","key":"10.1016\/j.neubiorev.2015.07.010_bib1930","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000074637","article-title":"Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease","volume":"48","author":"Watanabe","year":"2003","journal-title":"Neuropsychobiology"},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib1935","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1940","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib1945","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study","volume":"68","author":"Weintraub","year":"2010","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1950","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.26016","article-title":"Clinical spectrum of impulse control disorders in Parkinson's disease","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1955","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.biopsych.2006.11.032","article-title":"Spatiotemporal pattern of striatal ERK1\/2 phosphorylation in a rat model of Levodopa\u2013induced dyskinesia and the role of dopamine D1 receptors","volume":"62","author":"Westin","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib1960","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/7854_2009_27","article-title":"Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse","volume":"3","author":"Willuhn","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"5","key":"10.1016\/j.neubiorev.2015.07.010_bib1965","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.cct.2012.05.003","article-title":"Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world","volume":"33","author":"Winhusen","year":"2012","journal-title":"Contemp. Clin. Trials."},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib1970","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrn1406","article-title":"Dopamine, learning and motivation","volume":"5","author":"Wise","year":"2004","journal-title":"Nat. Rev."},{"issue":"10","key":"10.1016\/j.neubiorev.2015.07.010_bib1975","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.tins.2009.06.004","article-title":"Roles for nigrostriatal \u2013 not just mesocorticolimbic \u2013 dopamine in reward and addiction","volume":"32","author":"Wise","year":"2009","journal-title":"Trends Neurosci."},{"issue":"Suppl. 5","key":"10.1016\/j.neubiorev.2015.07.010_bib1980","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00415-008-5010-5","article-title":"Parkinson's disease-related disorders in the impulsive-compulsive spectrum","volume":"255","author":"Wolters","year":"2008","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1985","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF02251203","article-title":"Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease","volume":"5","author":"Wu","year":"1993","journal-title":"J. Neural Transm. Park. Dis. Dement. Sect."},{"issue":"3","key":"10.1016\/j.neubiorev.2015.07.010_bib1990","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1471-4159.1992.tb08365.x","article-title":"Quantitation of rat dopamine transporter mRNA: effects of cocaine treatment and withdrawal","volume":"59","author":"Xia","year":"1992","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.neubiorev.2015.07.010_bib1995","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00213-012-2812-z","article-title":"Effect of repeated treatment with topiramate on voluntary alcohol intake and beta-endorphin plasma level in Warsaw alcohol high-preferring rats","volume":"225","author":"Zalewska-Kaszubska","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neubiorev.2015.07.010_bib2000","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archneur.62.4.601","article-title":"Sex Differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study","volume":"62","author":"Zappia","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neubiorev.2015.07.010_bib2005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2012.12.011","article-title":"Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat","volume":"70","author":"Zengin-Toktas","year":"2013","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.neubiorev.2015.07.010_bib2010","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.0711839105","article-title":"Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in levodopa treatment of an animal model of Parkinsonism","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763415001955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763415001955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T18:17:42Z","timestamp":1748542662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763415001955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":380,"alternative-id":["S0149763415001955"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2015.07.010","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2015.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}